Nach Dave has joined Exobiosphere as Head of Global Business Development
LUXEMBOURG – Exobiosphere, the world’s first space-based Contract Research Organization, is expanding its commercial reach with the appointment of Nach Dave as Head of Global Business Development.
Mr. Dave brings two decades of experience in the pharmaceutical and medical device industries, with a career spanning senior leadership roles in regulatory affairs, clinical operations, and business development. He has worked at major companies including Merck, Bristol Myers Squibb, Sanofi, and CROs like Premier Research and ICON, where he led global teams and clinical strategies across therapeutic areas including oncology, immunology, and rare diseases.
Nach has worked directly with top regulatory agencies like the FDA and EMA, where he’s helped shape drug development strategy and led the approval process for new therapies and medical devices. He’s been involved in more than 15 international clinical trials and regularly speaks at global healthcare conferences. Alongside his industry work, he also taught future leaders in regulatory science as an associate professor at Long Island University, which is known for programs in health sciences, business, education, and pharmacy, among others.
“He doesn’t just know the industry—he moves it forward,” said Kyle Acierno, CEO of Exobiosphere. “As we introduce orbital R&D to pharma and biotech partners, Nach’s expertise will be key in building our global partnerships and finding new and innovative ways to bridge space and terrestrial workflows.”
Nach shared, “Joining Exobiosphere is an opportunity to pioneer something transformative. I’ve spent 20 years helping life sciences companies bring therapies to patients—now I get to help reimagine how that discovery happens, in space.”
Welcoming Nach marks a new chapter as Exobiosphere strengthens its global business development and prepares for its first launch, offering a breakthrough platform for space-enabled drug screening.
About Exobiosphere
Exobiosphere is the world’s first contract research organization dedicated to high-throughput testing and drug discovery in space. By combining space-grade lab automation, microgravity research, and advanced analytics, the company helps pharmaceutical, biotech, and healthcare partners enhance scientific discovery and accelerate product development. Its Orbital High-Throughput Screening Device (OHTS) is designed to uncover novel cellular and disease behaviors in a microgravity environment—insights that are difficult or impossible to replicate on Earth. Headquartered in Luxembourg at the House of BioHealth, Exobiosphere’s mission is to shorten R&D timelines and bring safer, more effective treatments to market for patients worldwide.
